Table 1.
Demographic characteristics of patients with cirrhosis (n = 236).
Table 2.
Median values of laboratory parameters and scores according to the Child-Pugh score, D’Amico staging (compensated and decompensated cirrhotic patients) and the extent of portal hypertension.
Fig 1.
Correlation of Von Willebrand factor antigen (vWF-Ag) and CSPH.
Mean values of vWF-Ag shown in boxplots for a cohort of patients with and without CSPH each.
Fig 2.
Correlation of aspartate aminotransferase to platelet ratio index (APRI) and CSPH.
Mean values of APRI shown in boxplots for a cohort of patients with and without CSPH each.
Fig 3.
Correlation of VITRO (VWF-Ag/platelets) score and CSPH.
Mean values of VITRO score shown in boxplots for a cohort of patients with and without CSPH each.
Fig 4.
Correlation of enhanced liver fibrosis test (ELF) test and CSPH.
Mean values of ELF test shown in boxplots for a cohort of patients with and without CSPH each.
Fig 5.
Correlation of transient elastography (TE; kPa) and CSPH.
Mean values of TE shown in boxplots for a cohort of patients with and without CSPH each.
Fig 6.
ROC analysis shows the ability of Von Willebrand factor antigen (vWF-Ag) predicting clinically significant portal hypertension (CSPH).
ROC analysis showing the diagnostic ability of vWF-Ag detecting CSPH with an AUC of 0.79.
Fig 7.
ROC analysis shows the ability of aspartate aminotransferase to platelet ratio index (APRI) predicting clinically significant portal hypertension (CSPH).
ROC analysis showing the diagnostic ability of APRI detecting CSPH with an AUC of 0.62.
Fig 8.
ROC analysis shows the ability of VITRO (VWF-Ag/platelets) score predicting clinically significant portal hypertension (CSPH).
ROC analysis showing the diagnostic ability of VITRO score detecting CSPH with an AUC of 0.86.
Fig 9.
ROC analysis shows the ability of enhanced liver fibrosis test (ELF) predicting clinically significant portal hypertension (CSPH).
ROC analysis showing the diagnostic ability of ELF test detecting CSPH with an AUC of 0.68.
Fig 10.
ROC analysis shows the ability of transient elastography (TE) predicting clinically significant portal hypertension (CSPH).
ROC analysis showing the diagnostic ability of TE detecting CSPH with an AUC of 0.92.
Fig 11.
ROC analysis shows the ability of the combination of TE and VITRO score predicting clinically significant portal hypertension (CSPH).
ROC analysis showing the diagnostic ability of TE in combination with VITRO score detecting CSPH with an AUC of 0.96.